Table 3.
Recommendations for Active Tuberculosis Treatment in Pregnant Women
| CDC | WHO | |
|---|---|---|
| Regimen (regardless of HIV status) | INH, RIF or rifabutin, and EMB × 2 mo Followed by: INH and RIF or rifabutin × 4–7 moa Pyridoxine supplementation Pyridoxine supplementation | INH, RIF, pyrazinamide, and EMB × 2 mo Followed by: INH and RIF × 4 moa Pyridoxine supplementation |
| Dosing frequency | Daily | Daily; 3× wk allowed with DOTS |
| Monitoring | Monthly hepatic panels | — |
| Newborn assessment | — | After active TB ruled out, new-born should receive INH × 6 mo, followed by BCG vaccine |
| Other recommendations | — | Vitamin K administration to newborn if mother taking RIF to decrease risk of neonatal hemorrhage |
aVaries based on drug resistance and anatomic location of TB infection (central nervous system, bone, joint involvement may require longer treatment). BCG, Bacillus Calmette-Guérin; CDC, Centers for Disease Control and Prevention; DOTS, directly observed treatment strategy; EMB, ethambutol; HIV, human immunodeficiency virus; INH, isonicotinylhydrazine; TB, tuberculosis; RIF, rifampin; WHO, World Health Organization.